Neurol. praxi. 2013;14(6):292-296

Familial amyloid polyneuropathy

doc.MUDr.Peter Špalek, PhD.
Centrum pre neuromuskulárne ochorenia, Neurologická klinika SZU, Univerzitná nemocnica Bratislava &ndash, Ružinov

Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a severe hereditary neuropathy due to deposition of mutant protein transtyretin

(TTR) as amyloid. TTR-FAP is primarily characterized by sensory, motor and autonomic neuropathy and/or cardiomyopathy.

As TTR-FAP is a progressive, disabling and life-threatening polyneuropathy, it is important to secure an accurate diagnosis as soon as

possible. It is important to suspect de novo TTR-FAP among patients with idiopathic progressive peripheral neuropathies. Especially

in elderly TTR-FAP should be considered as a chameleon-like-neuropathy mimicking a large spectrum of peripheral neuropathies.

Laboratory tests (e.g. salivatory gland biopsy, nerve biopsy) are specific to identify amyloid deposits, but not enough sensitive. TTR

gene sequencing is the most sensitive diagnostic method. 113 mutations in the TTR gene are known to promote the amyloid process.

TTR Val30Met is the most frequent mutation (> 60 %), the Slovak patients have a rare mutation Val71Ala. If untreated the disease has an

inexorable progressive course and death occurs 10 years of symptoms onset. Because the mutant form of TTR is produced mainly in the

liver, orthotopic liver transplantation was initiated in 1990 in order to halt the progression of the disease. Liver transplantation was, until

recently, the only available treatment but is associated with significant morbidity and mortality. Tafamidis is the first drug that selectively

binds to transthyretin preventing its dissociation into amyloid. Tafamidis was shown to delay disease progression and was well tolerated.

In november 2011 was tafamidis approved in Europe to treat neuropathy in stage 1 TTR-FAP patients.

tafamidis.

Keywords: familial amyloid polyneuropathy, transthyretin, TTR gene mutations, de novo TTR-FAP, DNA diagnosis, liver transplantation,

Published: December 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Špalek P. Familial amyloid polyneuropathy. Neurol. praxi. 2013;14(6):292-296.
Download citation

References

  1. Adams D, Lozeron P, Theaudin M, Mincheva Z, Cauquil C, Adam C, Signate A, Vial C, Maisonobe T, Delmont E, Franques J, Vallat JM, Sole G, Pereon Y, Lacour A, Echaniz-Laguna A, Misrahi M, Lacroix C, French Network for FAP. Regional differences and similarity of familial amyloidosis with polyneuropathy in France. Amyloid 2012; 19(Suppl 1): 61-64. Go to original source... Go to PubMed...
  2. Adams D. Recent advances in the treatment of familial amyloid neuropathies. Ther Adv Neurol Dis 2012; 6: 129-139. Go to original source... Go to PubMed...
  3. Adams D. TTR-FAP: Clinical experience. In: Advances and Research on TTR Amyloidosis: Improving Diagnosis, Improving Outcomes. Barcelona, 2013: 20-21.
  4. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda SI, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013; 8: 31. Cloi.10.1186/1750-1172-8-31. Go to original source... Go to PubMed...
  5. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952; 75: 408-427. Go to original source... Go to PubMed...
  6. Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013; 29: 63-76. Go to original source... Go to PubMed...
  7. Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceicao IM, Schmidt HHJ, Trigo P, Kelly JW, Chan J, Packman J, Wilson A, Grogan DR. Tafamidis for transthyretin familial amyloid polyneuropathy - a randomized, controlled trial. Neurology 2012; 79: 785-792. Go to original source... Go to PubMed...
  8. Conceicao I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 2007; 35: 116-118. Go to original source... Go to PubMed...
  9. Conceicao I, Evangelista T, Castro J, Pereira P, Silvester A, Coutinho CA, de Carvalho M. Acquired amyloid neuropathy in Portuguese patient after domino liver transplantation. Muscle Nerve 2010; 42: 836-839. Go to original source... Go to PubMed...
  10. Ericzon BG, Larsson M, Wilczek HE. Domino liver transplantation: risk and benefits. Transplant Proc 2008; 40: 1130-1131. Go to original source... Go to PubMed...
  11. Ericzon BG. Liver transplantation for TTR-FAP. In: Advances and Research on TTR Amyloidosis: Improving Diagnosis, Improving Outcomes. Barcelona, 2013: 20-21.
  12. Kato-Motozaki Y, Ono K, Shima K, Morinaga A, Machiya T, Nozaki I, Shibata-Hamaguchi A, Furukawa Y, Yanase D, Ishida C, et al. Epidemiology of familial amyloid polyneuropathy in Japan: Identification of a novel endemic focus. J Neurol Sci 2008; 270: 133-140. Go to original source... Go to PubMed...
  13. Lladó L, Baliellas C, Casasnovas XC, Ferrer I, Fabregat J, Ramos E, Castellote J, Torras J, Xiol X, Rafecas A. Risk of transmission of systematic transthyretin amyloidosis after domino liver transplantation. Liver Transpl 2010; 16: 1386-1392. Go to original source... Go to PubMed...
  14. Oliverius M, Hampl F, Adamec M, Skladaný L, Špalek P, Gabriš V, Trunečka P, Kothaj P. První česko-slovenská domino transplantace jater. Rozhl chir 2011; 90: 122-126. Go to PubMed...
  15. Planté-Bordeneuve V, Suhr OB, Maurer MS, Grogan BWDR, Coelho T. The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin 2013; 29: 77-84. Go to original source... Go to PubMed...
  16. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011; 12:1086-1097. Go to original source... Go to PubMed...
  17. Simmons Z, Specht ChS. The neuromuscular manifestations of amyloidosis. Clin J Neuromusc Dis 2010; 11: 145-157. Go to original source... Go to PubMed...
  18. Suhr OB, Ericzon BG. Selection of hereditary transthyretin amyloid patients for liver transplantation: the Swedish experince. Amyloid 2012; 19(Suppl 1): 78-80. Go to original source... Go to PubMed...
  19. Suhr OB, Friman S, Ericzon BG. Early liver transplantation improves familial amyloidotic polyneuropathy patients´ survival. Amyloid 2005; 12: 233-238. Go to original source... Go to PubMed...
  20. Špalek P, Chandoga J, Cibulčík F, Skladaný Ľ. Familiárna amyloidná polyneuropatia - aktuálne trendy v diagnostike a liečbe. Ces Slov Neurol Neurochir 2012; 75/108: S42.
  21. Špalek P, Urminská I. Familial amyloid polyneuropathy in Slovak Republic. European Advanced Postgraduate Course on Transthyretin-Associated Amyloidosis. Porto, Portugal, May 13-17, 2013.




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.